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Oncogenic Sox2 regulates and 
cooperates with VRK1 in cell cycle 
progression and differentiation
David S. Moura1,2, Isabel F. Fernández1, Gema Marín-Royo1, Inmaculada López-Sánchez1, 
Elena Martín-Doncel1,2, Francisco M. Vega3,4 & Pedro A. Lazo1,2
Sox2 is a pluripotency transcription factor that as an oncogene can also regulate cell proliferation. 
Therefore, genes implicated in several different aspects of cell proliferation, such as the VRK1 
chromatin-kinase, are candidates to be targets of Sox2. Sox 2 and VRK1 colocalize in nuclei of 
proliferating cells forming a stable complex. Sox2 knockdown abrogates VRK1 gene expression. 
Depletion of either Sox2 or VRK1 caused a reduction of cell proliferation. Sox2 up-regulates VRK1 
expression and both proteins cooperate in the activation of CCND1. The accumulation of VRK1 protein 
downregulates SOX2 expression and both proteins are lost in terminally differentiated cells. Induction 
of neural differentiation with retinoic acid resulted in downregulation of Sox2 and VRK1 that inversely 
correlated with the expression of differentiation markers such as N-cadherin, Pax6, mH2A1.2 and 
mH2A2. Differentiation-associated macro histones mH2A1.2and mH2A2 inhibit CCND1 and VRK1 
expression and also block the activation of the VRK1 promoter by Sox2. VRK1 is a downstream target of 
Sox2 and both form an autoregulatory loop in epithelial cell differentiation.
Sox2 is a transcription factor that has a major role in cellular reprogramming in cooperation with other factors 
such as Oct4, c-myc and Klf41. In addition to this role in reprogramming, Sox2 also participates in self-renewal 
of stem cells as well as in proliferation and specific cell differentiation, which leads to the formation of tissues 
after several rounds of cell division. Therefore, it is likely that Sox2 has an important role in the regulation of cell 
proliferation, and in this context its expression also might function as an oncogene.
Sox2 plays several roles in stem, proliferating and differentiating cells2. Sox2 has been shown to participate in 
the regulation of cell proliferation, where it works either as an activator or an inhibitor3 and Sox2 is required for 
self-renewal of stem cells, normal or tumoral4, which implies cell division. Furthermore, Sox2 is also implicated 
in tumor biology. The human SOX2 gene, located in 3q26.3-q27, is frequently amplified and overexpressed in 
several types of carcinomas5,6, which is consistent with its oncogenic role. Expression of Sox2 is an initiating event 
in the development of squamous cell carcinomas7, where it regulates tumor stem cells8 and also functions as an 
oncogene5,9,10. Furthermore, knockdown of Sox2 reduces proliferation of tumor cells from glioblastomas11, osteo-
sarcomas12, breast cancer8 and small-cell lung cancer9, which supports an implication of Sox2 in the proliferation 
phenotype. These observations mean that Sox2 has to establish a functional regulatory link with other proteins 
implicated in the control of cell proliferation.
VRK1 is a Ser-Thr chromatin kinase that forms complexes with histones13–17 and transcription factors18–21. 
Besides, VRK1 is required for several processes in cell division22. VRK1 participates in G0 exit and entry in G117,23 
and its depletion results in a cell cycle arrest24. VRK1 is also necessary for chromatin compaction in G2/M15, reg-
ulation of nuclear envelope assembly and disassembly25,26, as well as Golgi fragmentation in mitosis27 and regula-
tion of Cajal Bodies assembly in cell cycle28. In normal epithelia, VRK1 is expressed in a cell subpopulation of the 
epithelial basal layer17, at a frequency consistent with the initiation of cell division by an epithelial stem cell that 
leads to formation of the proliferation compartment. Expression of VRK1 in squamous epithelia is consistent with 
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this role, where it is present in dividing cells, colocalizing with Ki6729 and p6317, but not in differentiated cells17,29. 
Depletion of VRK1 also causes a reduction in cell proliferation17,30. This suggested a potential role for VRK1 in the 
initial asymmetric division of stem cells in which two types of cells are generated. One stem cell, and another cell 
destined for further expansion and differentiation through mechanisms which also require the activity of VRK117.
Cell proliferation and cell differentiation are processes sequentially organized in tissue formation, and they 
have different roles. One is associated to expansion of the cellular population, while the other is implicated in the 
acquisition of the final cell phenotype required to form a tissue, and is an inhibitor of cell proliferation17,29,30. After 
a cell decides to divide and differentiate there are a series of biological steps that control the switch from division 
to differentiation. In this context genes controlling cell division are very likely targets of its transcriptional activ-
ity, among which VRK122,31 is a potential candidate to be regulated by Sox2 since both proteins are associated 
with the proliferation phenotype. In this report we have studied and characterized the functional interaction 
between the transcription factor Sox2 and the VRK1 chromatin kinase in the context of cellular proliferation and 
differentiation.
Results
VRK1 and Sox2 colocalize in normal epithelium and in carcinoma cell lines. The implication of 
both Sox2 and VRK1 in cell proliferation led us to determine whether there is a relationship between these two 
proteins. Initially it was determined the pattern of Sox2 and VRK1 protein expression in a stratified squamous 
epithelium from a normal human tonsil. VRK1 and Sox2 presented a similar localization, manifested by their 
staining within the amplification compartment, where proliferating cells are located. The expression of both pro-
teins decreased as epithelial cells were terminally differentiated (Fig. 1a). The colocalization of Sox2 and VRK1 
in the same nuclei of normal epithelial cells was confirmed by their overlapping staining detected by confocal 
immunofluorescence (Fig. 1b).
To study the potential relationship between Sox2 and VRK1, we also determined their presence in several cell 
lines: HEK293T cells, MCF7 and MDA-MB-231 breast cancer cell lines, and N-tera2 (NT2)32 cells, a teratocar-
cinoma cell line that can differentiate into neurons. NT2 cells have high levels of both Sox2 and VRK1 proteins 
(Fig. 1c, top). Low endogenous levels of Sox2 became detectable in MDA-MB231 cells by immunoblots only 
after immunoprecipitation (Fig. 1c, bottom). Although expression levels of Sox2 varied among cell lines, nuclear 
colocalization of Sox2 and VRK1 was confirmed by immunofluorescence in NT2 cells (Fig. 1d), MDA-MB-231 and 
MCF7 cells (Supplementary Fig. S1a). The nuclear fluorescence of Sox 2 is three fold higher in NT2 cells (Fig. S1b).
Sox2 forms a stable protein complex with VRK1. VRK1 is a chromatin kinase that regulates his-
tones15,16 and also forms stable complexes with several transcription factors such as p5319, ATF221, c-Jun20 and 
CREB118, which are also its phosphorylation targets. Sox2 is a SRY-related HMG-box transcription factor that 
is phosphorylated in several residues33. Therefore, we hypothesized that VRK1 could also be forming a stable 
protein complex with the Sox2 transcription factor. To detect this possible interaction we performed reciprocal 
immunoprecipitations of endogenous VRK1 and Sox2 proteins from MDA-MB-231, NT2 and HEK293T cells. In 
the three cell lines Sox2 was detected in the VRK1 immunoprecipitate, and reciprocally VRK1 was also detected 
in the Sox2 immunoprecipitate (Fig. 2a). This stable VRK1-Sox2 protein interaction was further confirmed by 
either immunoprecipitation of transfected tagged-proteins (Supplementary Fig. S2a), and the interaction was also 
dependent on the amount of transfected protein (Fig. S2b). This interaction Sox2-VRK1 interaction was further 
confirmed by performing GST-VRK1 pulldown (Supplementary Fig. S2c), or immunoprecipitation experiments 
(Fig. S2d) and using deletion fragments of the VRK1 protein. Because VRK1 is a Ser-Thr kinase, the potential 
phosphorylation of Sox2 by VRK1 was demonstrated using kinase active and inactive VRK1. VRK1, but not 
kinase-dead VRK1(K179E), phosphorylated Sox2 (Fig. 2b). Therefore, VRK1 is one of the kinases phosphoryl-
ating Sox2. Sox proteins share an HMG motif but have different structure and functions34. Therefore, we also 
tested if VRK1 can interact with Sox4, which has different roles. An interaction between VRK1 and Sox4 was not 
detected in immunoprecipitation or GST-pulldown assays (Fig. 2c). In addition, VRK1 also did not interact with 
endogenous c-myc protein (Fig. 2d), whose expression is regulated by VRK117.
Depletion of Sox2 results in loss of VRK1 and cell proliferation. The co-localization of Sox2 and 
VRK1 in the proliferation compartment, as well as their physical interaction suggested that both might contribute 
to control of cell proliferation. Fist we determined the effect of Sox2 knockdown on the levels of Sox2 and VRK1 
in NT2 cells. Depletion of Sox2 resulted in the loss of Sox2 and VRK1, suggesting that VRK1 can be a downstream 
target of Sox 2 (Fig. 3a). Sox2 depletion also caused a reduction in cell number by immunofluorescence. Next, 
because both proteins have been associated to proliferation17,35, we tested if depletion of either Sox2 or VRK1 in 
MDA-MB-231 cells can have an effect on cell proliferation. Depletion of Sox2, or VRK1, caused a similar reduc-
tion in the rate of cell duplication (Fig. 3b). Depletion of either of these proteins was also manifested by the loss of 
phospho-Rb, cyclins D1 and A, PCNA, all them associated to active cell proliferation (Fig. 3c). Depletion of Sox2, 
or VRK1, also resulted in accumulation of p27, an inhibitor of cell cycle progression (Fig. 3c).
Sox2 activates VRK1 gene expression. The regulation of VRK1 gene expression by Sox2 was initially 
studied in MDA-MB-231 cells that were infected with a retroviral construct overexpressing Sox2. High levels 
of Sox2 induced an increase of endogenous VRK1 protein that was detected by immunofluorescence (Fig. 4a) 
and by immunoblot analysis (Fig. 4b). In both approaches, the increase of VRK1 levels was similar. This effect 
on VRK1 might be due to either increased gene expression or protein stability. The effect of Sox2 overexpression 
caused an increase in expression of VRK1 mRNA levels (Fig. 4c). A similar effect of Sox2 overexpression on 
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VRK1 expression was observed in MCF-7 cells (Supplementary Fig. S3a–c). These results suggested that Sox2 is 
regulating the VRK1 gene.
Because Sox2 is a transcription factor, we next tested whether the VRK1 (− 1028 to + 52) proximal gene pro-
moter, cloned in a luciferase reporter plasmid, was regulated by Sox2. The proximal VRK1 gene promoter was acti-
vated by overexpression of Sox2 (Fig. 4d). A similar result was obtained with HEK293T cells in which the VRK1 
(− 1028 + 52) gene promoter was also activated in a dose dependent manner by Sox2 (Supplementary Fig. S3d). 
However, Sox2 has no effect on the activation of VRK1 promoter comprised between residues − 264 to + 52 
(Supplementary Fig. S4). This shorter promoter region shows a higher level of expression, reflecting the lack of 
some regulatory elements. These results indicated that the effect of Sox2 on VRK1 promoter is mediated by the 
region comprised between residues − 1028 to − 264.
Sox2 and VRK1 cooperate in the activation of CCND1 gene expression. Both Sox28 and VRK118 
have been implicated in the regulation of CCND1 gene expression, coding for cyclin D1, which is necessary for 
cell cycle progression. Sox2 is a transcriptional factor that initiates cell division in the stem cell compartment7 and 
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Figure 1. Sox2 and VRK1 expression in normal epithelium and tumor cell lines. (a) Expression of 
Sox2 and VRK1 in stratified epithelium from a normal human tonsil. VRK1 was detected with rabbit 
polyclonal VC1 antibody, and Sox2 was detected with murine mAb, by immunohistochemistry. (b) Sox2 
and VRK1 in tonsil epithelium were detected by confocal immunofluorescence. (c) Expression of Sox2 
and VRK1 protein was detected by immunoblot analysis. In MDA-MB-231 cells Sox 2 was determined 
after immunoprecipitation of endogenous Sox2 (bottom) with a monoclonal antibody and detected with a 
polyclonal antibody. (d) Colocalization of Sox2 and VRK1 in nuclei of NT2 cells by confocal microscopy. To 
the right is shown the profile of the signal in the plane. Similar co-localization of Sox2 and VRK1 was detected 
in human MCF7 and MDA-MB-231cell lines (Supplementary Fig. S1a). F: lymphoid follicle.
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is a known regulator of the G1/S transition in cell cycle, which is mediated by cyclin D18. VRK1 also facilitates 
cell cycle progression and is able to activate the CCND1 gene promoter29, an effect that is mediated by phospho-
rylation of CREB118, and its depletion causes a cell cycle arrest in G0/G117. Therefore, we tested whether VRK1 
and Sox2 can cooperate in the activation of the proximal CCND1 gene promoter. Sox2 and VRK1 individually 
caused an activation of the CCND1 gene promoter (Fig. 5a,b), which is approximately five fold stronger in the 
case of Sox2 (Fig. 5b). But the combination of both Sox2 and VRK1 resulted in a higher activation of CCND1 gene 
expression (Fig. 5c), which was consistent with a synergistic effect. Therefore, we concluded that Sox2 and VRK1 
proteins synergistically cooperate in the activation of CCND1 gene expression and thus can contribute together 
to cell cycle progression and proliferation.
VRK1 levels modulate SOX2 gene expression. The activity of VRK1 is controlled by an autoregulatory 
loop with some of its targets as has been described in the context of p5336,37. Therefore, we explored whether 
there is a cross regulation between VRK1 and Sox2 expression. Initially, the effect of VRK1 depletion on the level 
of Sox2 was determined by immunofluorescence. Depletion of VRK1 with two different siRNA resulted in an 
increased of the intracellular level of Sox2 protein in MDA-MB-231 cells (Fig. 6a). In cells that were arrested by 
serum deprivation for forty eight hours there was no effect on the level of endogenous Sox2 protein (Fig. 6a). This 
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Figure 2. Sox2-VRK1 protein interaction. (a) Human endogenous Sox2 interacts with human endogenous 
VRK1. The VRK1-Sox2 intracellular complex was detected in MDA-MB-231(top), NT2 (center) and HEK293T 
(bottom) cells. Cell lysates were immunoprecipitated with a mAb anti-Sox2 mAb ( E-4) or anti-VRK1 (1B5)64. 
Human endogenous VRK1 was detected in immunoblots with anti-VRK1 (VC1) antibody64 and Sox2 was 
detected with Y-17 antibody. Control immunoprecipitations were done with a nonspecific antibody. The 
Sox2-VRK1 interaction was confirmed in transfection experiments with tagged HA-VRK1 and Flag-Sox2 
(Supplementary Fig. S1b) and in pulldown assays using GST-VRK1 (Supplementary Fig. S1c). (b) In vitro kinase 
assay using VRK1 or kinase-dead VRK1 (K179E) with immunoprecipitated myc-Sox2 as substrate. (c) Lack 
of interaction between VRK1 and Sox4. Tagged Sox4 wt and mutants (S395X or A350P) were co-transfected 
with either VRK1-myc (left) or GST-VRK1 (right) for either immunoprecipitation (IP) or pull down assays 
(PD) respectively. (d) Lack of interaction between endogenous VRK1 and c-myc. Endogenous VRK1 was 
immunoprecipitated with anti-VRK1 (1B5)64.
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indicated that the effect on VRK1 is not an indirect consequence of his role in arresting cell cycle17. The effect is 
dependent on the kinase activity of VRK1 since VRK1 is kinase-inactive in the absence of serum38.
To determine whether the effect of VRK1 depletion on Sox2 protein levels was due to altering SOX2 gene 
expression we determined its mRNA levels by qRT-PCR. VRK1 depletion resulted in a significant increase in Sox2 
mRNA (Fig. 6b). Similar results were obtained in MCF7 (Supplementary Fig. S5) and NT2 cells (Supplementary 
Fig. S6).
To further confirm the effect of VRK1 on the regulation of SOX2 gene expression, the opposite experiment was 
performed. VRK1 was overexpressed using a retroviral construct resulting in downregulation of Sox2 and a loss 
of Sox2 nuclear fluorescence (Fig. 7a). This effect was the consequence of a reduction in the level of Sox2 mRNA 
(Fig. 7b). This effect was also confirmed using a stable HeLa cell line overexpressing VRK1 (Supplementary Fig. S7). 
Therefore, the combined results from knockdown and overexpression experiments indicated that there is a cross 
regulation between Sox2 and VRK1 and that VRK1 contributes to the downregulation of SOX2 gene expression.
Expression of Sox2 and VRK1 in NT2 cell differentiation induced by retinoic acid. Sox2 plays 
and important role in the early decision of stem cells7, and VRK1 has a role in initiation of cell proliferation17,22,30. 
Since initiation of lineage differentiation requires an asymmetric cell division we decided to study the fate of Sox2 
and VRK1 along the NT2 cell differentiation process induced with retinoic acid. Induction of cell differentiation 
resulted in a significant loss of stem cell markers including Sox2, Oct4, and Nanog: and also of VRK1, cyclins 
D1 and B1 proteins, which represent markers of proliferation (Fig. 8a). In addition differentiation markers such 
Pax6, N-cadherin, p27 and phospho-CREB are increased during RA-induced differentiation as expected. Also 
markers that are lost during RA-induced differentiation such as vimentin were determined (Fig. 8a). All of the 
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Figure 3. Sox2 knockdown results in loss of VRK1 and of cell proliferation. (a) Depletion of Sox2 in NT2 
cells. Sox2 was knocked down and the level of Sox2 protein determined by immunofluorescence and western 
blot. One hundred cells were used for immunofluorescence quantification with the LAS Lite program. Sox2 
was detected with a mouse monoclonal anti- Sox2 (E-4, 1:100). VRK1 was detected using a rabbit polyclonal 
anti-VRK1 antibody (1:200). (Student’s Test: * < 0.05; * * < 0.005; * * * < 0.0005). siC: si-control. The western 
blot with the knockdown of Sox2 is shown to the right. (b) Effect of silencing Sox2 or VRK1 on the rate of 
cell proliferation in MDA-MB-231 cells. An equal number of cells (200 000) were seeded and counted every 
twenty-four hours (left). The results show the mean of three experiments, in which each point was determined 
in triplicate. (c) Expression of proteins associated to cell cycle progression. Cells were also used to determine 
the expression of different proteins associated with proliferation (center). Because of the low number of cells the 
level of Sox2 was determined by qRT-PCR (right). siC: si-control, siS: si-Sox2, siV: si-VRK1-02.
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markers studied presented the expected variation as differentiation progressed in time (Fig. 8a). The reduction in 
levels of Sox2, VRK1 (Fig. 8b), Oct4 and Nanog protein levels (Supplementary Fig. S8) were also confirmed by the 
loss of their nuclear fluorescence. The differentiation state of NT2 cells was also confirmed by the morphological 
reorganization of α -tubulin induced by RA (Supplementary Fig. S8). To determine whether these changes in 
protein levels were due to modifications in gene expression we also determined, by qRT-PCR, the expression of 
SOX2, OCT4, VRK1, H2AFY, and H2AFY2. The two latter genes code for macrohistones mH2A1.2 and mH2A2 
that inhibit cell proliferation and are associated with terminal differentiation39,40. Retinoic acid (RA) induced a 
downregulation of SOX2, OCT4 and VRK1 mRNA; in addition RA also caused an upregulation of macroH2A1.2 
and macroH2A2 mRNA to very high levels in the last days of the differentiation process (Fig. 8c). The differenti-
ation phenotype of NT2 cells was confirmed by detecting the corresponding increase in N-cadherin, β II-tubulin, 
Pax6 and CREB phosphorylated in Ser133 (Fig. 8a). Thus there is an inverse temporal correlation between the 
loss of markers regulating cell stemness and proliferation and the increase of those markers associated with cell 
differentiation.
Inhibition of VRK1 and CCND1 gene expression by macroH2A histones. The downregulation of 
stem genes concomitant with differentiation are mediated by an exchange of histones in which histone H2A is 
replaced by macro-histones that have a larger C-terminal region41,42. Macro-histones H2A (mH2A) are histone 
variants that are associated with differentiated cells and inhibit gene transcription43,44, as shown for mH2A1.2 and 
mH2A2 (Fig. 8c). Also macro histone H2A1.2 is known to inhibit the activity of VRK1 by their direct physical inter-
action14. Therefore, it was tested if macro-histones were able to regulate the VRK1 and CCND1 gene promoters. 
The differentiation associated mH2A1.2 and mH2A2 inhibited VRK1 gene promoter in a dose dependent man-
ner (Fig. 9a,b). However, the proliferation associated mH2A1.1 did not inhibit the VRK1 promoter. Next, we 
determined if these macro-histones were also able to inhibit the effect of Sox2 on the VRK1 gene promoter. 
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Figure 4. Sox2 activates endogenous VRK1 gene expression. (a) Effect of Sox2 overexpression in 
MDA-MB-231 cells infected with the retroviral plasmid pBabe-Sox2. Cells were studied by confocal 
immunofluorescence and the quantification of the fluorescence is shown in the graph (right). (b) Effect of  
Sox2 overexpression on endogenous VRK1 protein in cell lysates of MDA-MB-231 cells determined by 
immunoblot. (c) Levels of endogenous VRK1 RNA from control or infected MDA-MB-231 cells with pBabe-
Sox2. Sox2 and VRK1 RNA levels were determined by qRT-PCR. (d) Effect of overexpression of Sox2 on 
the proximal VRK1 promoter (− 1028 + 52) in a luciferase reporter construct. At the bottom is shown the 
expression of transfected Sox2. Reporter gene experiments were performed three times, and each individual 
luciferase assay was determined in triplicate.
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The differentiation-induced mH2A1.2 and mH2A2 proteins were able to block the activating effect of Sox2 on 
the VRK1 proximal promoter (Fig. 9c). Finally, we also showed that mH2A1.2 and mH2A2, but not mH2A1.1, 
also inhibited the CCND1 promoter in a dose dependent manner (Fig. 9d). Therefore, we concluded that 
macro-histones associated with differentiation inhibit the proliferative signals acting on the VRK1 and CCND1 
promoters, as well as prevent the effect of Sox2 on VRK1 expression.
Discussion
The expression of Sox2 within the amplification compartment of the epithelium suggested that Sox2 has a role in 
the control of cell proliferation, particularly since it also colocalizes with VRK1 in these cells, which has also been 
associated to the p6317 and Ki6729 proliferation markers. This Sox2 expression in tonsil stratified epithelium is 
analogous to its expression in the pituitary gland45 and esophagus epithelium2. The interaction between Sox2 and 
VRK1 in nuclei is consistent with the known interaction of VRK1 with several transcription factors such as p5319, 
ATF221, CREB18 or c-Jun20, as well as the p300 acetyltransferase transcriptional coactivator46. In addition, the 
phosphorylation of Sox2 by VRK1 can contribute to the regulation of its transcriptional activity or its integration 
in nuclear complexes with other nucleoproteins and will require further studies.
As cells initiate their first self-renewal asymmetric division it is necessary the cooperation of Sox2 with other 
proliferation associated proteins, among which the VRK1 is a potential candidate. At this stage Sox2 connects 
with VRK1, a chromatin kinase, associated to several aspect of cell proliferation22 as well to chromatin remod-
eling16. Thus, the regulation of VRK1 gene by Sox2 is fully consistent with a role for VRK1 as an initiator of cell 
proliferation17. Sox2 increases VRK1 gene expression by targeting its proximal promoter, but neither Sox2 nor 
VRK1 are direct regulators of cell cycle initiation and progression. Therefore they have to regulate key genes or 
proteins implicated in the regulation of cell cycle, among which CCND1 is a major candidate47. Thus, Sox2 and 
VRK1, as proliferation regulators, synergistically cooperate in the control of cell cycle specific genes, as is the 
case of CCND1 that is regulated by both Sox235 and VRK118. CCND1 gene expression is in part regulated by the 
CREB transcription factor18. In this context, it is important to note that CREB gene expression is regulated by 
Sox248 and CREB protein is phosphorylated and activated by VRK118. Therefore, it is likely that depending on 
levels of CREB-Ser133 phosphorylation there are different threshold of responses. In dividing cells low levels of 
phospho-CREB are required for cell cycle progression. But in cells that are differentiated and in which a different 
set of genes are required to fulfill their specific functions, a higher level of phosphorylation may be necessary. 
Thus, it is possible that in differentiated cells, Ser133 phosphorylation is mediated by different kinases, among 
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Figure 5. Sox2 and VRK1 cooperate in the activation of the human cyclin D1 (CCND1) promoter. Breast 
carcinoma MDA-MB-231 cells were transfected with 1 μ g of pA3-CyclinD1-Luc reporter that contains the 
proximal promoter (− 1745 + 134) and increasing amounts of plasmids expressing Sox2 and VRK1. Forty-eight 
hours after transfection, cell lysates were prepared and used for determination of luciferase activity. The results 
are the mean of three independent experiments in triplicate.
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which are calcium/calmodulin-dependent protein kinase types II and IV49. Therefore, CREB phosphorylation 
can have different roles depending on whether it is participating in cell cycle progression or in differentiation.
Accumulation of VRK1 protein also negatively down regulates Sox2, since cells are already determined, but 
proliferation is still necessary. The lower rate of VRK1 downregulation in differentiation is a consequence of the 
high stability of this protein17. As cells differentiate the accumulation of VRK1 protein can inhibit Sox2 expres-
sion, and also mH2A1.2 can inhibit the kinase activity of VRK114 that facilitate cell differentiation.
Differentiated cells do not divide and this implies the need for a downregulation of proliferative proteins. In 
this context as VRK1 reaches a high level, it is able to activate CCND1 by itself and also down-regulate SOX2 
by an unknown mechanism but that is likely to include regulation of the transcriptional complex. This latter 
effect is consistent with the upregulation of pluripotency transcription factors, Sox2, Oct4 and c-myc, caused by 
luteolin, an inhibitor of VRK150. Moreover, high VRK1 can stabilize p5319,51 and contribute to the necessary cell 
cycle arrest to permit differentiation. Inhibition of proliferation and facilitation of differentiation is mediated 
by changes in chromatin and this change is associated to incorporation of histone variants. For this remodeling 
of chromatin in differentiation, the role of macrohistones mH2A1.2 and H2A2 is very important because they 
inhibit the VRK1 promoter, and also prevent the effect of Sox2 on the VRK1 and CCND1 promoters.
The role of VRK1 within the tumor phenotype is complex, since it can function as an oncogene or tumor 
suppressor depending on the cellular context. VRK1 is strong facilitator of cell cycle progression15,17 and prolifer-
ation17,30, and many tumors have very high levels of VRK1 protein which is consistent with an oncogenic function 
of wild-type VRK1. High levels of VRK152,53 and Sox254,55 are markers of a poorer prognosis in breast cancer, 
which is a reflection of their contribution to expanding the tumor cell population. But VRK1 is also positive regu-
lator of p5319,24,51,56, and contributes to genomic stability by facilitating DNA damage responses16,38,57. In this latter 
context, the role of VRK1 is similar to that of other tumor suppressor genes or tumor predisposition genes. Thus, 
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Figure 6. VRK1 depletion upregulates SOX2 gene expression. (a) In MDA-MB-231 cells, human endogenous 
Sox2 levels increase, when VRK1 levels decrease. 72 hours after siControl, si-VRK1-02 and si-VRK1-09 
treatment, was performed the fixation and permeabilization of MDA-MB-231 cells. By immunofluorescence, 
human endogenous Sox2 was detected with a mouse monoclonal anti-Sox2 (E-4, 1:100). Human endogenous 
VRK1 was detected using a rabbit polyclonal anti-VRK1 antibody (1:200). DAPI (1:1000). In western blots, 
human endogenous VRK1 was detected with anti-VRK1 (1B5, 1:1000). Human endogenous Sox2 was detected 
using a goat polyclonal anti-Sox2 (Y-17, 1:500) and human β -actin was detected using a mAb anti-β -actin 
(1:5000). (b) VRK1 depletion caused a reduction of Sox2 mRNA detected by qRT-PCR. The experiment was 
determined three times in triplicate determinations. siCt: siControl; siV-02: siVRK1-02; siV-09: siVRK1-09.
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the complexity of VRK1 functions might be a reflection of its late appearance in evolution as organisms become 
more complex, and where VRK1 appears to be implicated in the coordination of diverse signaling processes and 
functions in vertebrates.
In this work we have identified a functional connection between Sox2 and VRK1. Initially Sox2 activates 
VRK1 gene expression and both proteins synergistically activate CCND1 expression that promotes cell prolifera-
tion. In addition VRK1 contributes to SOX2 downregulation to reduce proliferation and facilitate differentiation 
to which macrohistones contributes by completely shutting down Sox2 and VRK1 in terminally differentiated 
cells. But in the process of differentiation both are downregulated. The data shows a coordinated role for these 
proteins in the transition from cell division to cell differentiation (Fig. 10).
Material and Methods
Plasmids. For overexpression of human VRK1, cells were infected with pQCXIP-VRK1, retroviral plas-
mid containing full-length human VRK1, and used as a pool. Plasmid expressing VRK1, pCEFL-HA-VRK1 
has been described27,28,51,58. The proximal promoter of human VRK1 (− 1028 to + 52 and − 274 to + 52) were 
cloned in pGL2-basic (Promega, WI). Human CCND1 gene promoter was studied with pA3-CyclinD1-Luc (wt 
− 1745 + 134)59. Plasmids expressing macroH2A1.1 macroH2A1.2 and macroH2A2 were from M. Buschbeck43. 
Sox2: pCMV6-myc-Flag-Sox2 (Origene; Rockville, MD) or pBabe-Sox2. Sox4: pCDNA3.1-Sox4, pCD-
NA3.1-Sox4(S395X), and pCDNA3.1-Sox4(A350P)60.
Cell lines and Transfections. The following validated cell lines were used: HeLa, HEK293T, MCF7, 
MDA-MB-231 and NTera2(NT2)61 (ATCC-LGC, Teddington, UK). Cell lines were cultured in (DMEM) medium 
(Sigma-Aldrich; St-Louis, MO) with 10% fetal calf serum. For transient transfections, cells were transfected using 
polyethylenimine (PEI) reagent (Polysciences, Inc.; Warrington, PA) as reported27,62,63.
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Figure 7. VRK1 overexpression downregulates SOX2 gene expression. (a) MDA-MB-231 cells were 
transduced with pQCXIP (empty vector) or pQCXIP-VRK1 and selected with puromycin. The presence of 
Sox2 and VRK1 proteins in nuclei was determined by confocal microscopy (left) and the cell florescence was 
quantified (right). Sox2 was detected with a mouse monoclonal anti-Sox2 (E-4, 1:100). VRK1 was detected 
using a rabbit polyclonal anti-VRK1 antibody (1:200). VRK1 was detected, using a mouse monoclonal anti-
VRK1 (1B5, 1:1000). β -actin was detected using a mouse monoclonal anti-β -actin antibody (1:5000). (b) The 
levels of Sox2 and VRK1 RNA were determined by qRT-PCR in control (pQCXIP) and VRK1 transduced cells 
(pQCXIP-VRK1) cells. The effect occurs also at mRNA level.
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Knockdown of VRK1. VRK1 knockdown was performed using three different siRNA for VRK1 
(NM_003384): siVRK1-02 (siV1-02), siVRK1-03 (siV1-03) and siVRK1-09 (siV1-09) (Dharmacon 
RNA Technologies,). The sequences targeted by these VRK1 siRNA oligonucleotides were siVRK1-
01: GAAAGAGAGTCCAGAAGTA; siVRK1-02: CAAGGAACCTGGTGTTGAA; si-VRK1-03: 
GGAAUGGAAAGUAGGAUUA; and siVRK1-09: AGGUGUACUUGGUAGAUUA. Sox2 was knockdown with 
the SOX2 Trilencer-27 human siRNA (Origene, Rockville, MD). As negative control the “ON-TARGETplus 
siCONTROL Non-targeting siRNA” (siCt) (Dharmacon) was used. The efficiency of RNAi transfection was deter-
mined with “siGLO RISC-free siRNA” (DHARMACON) labelled with a red fluorochrome. All of them have been 
previously used. Cells were transfected with the indicated siRNA (20 nM), using Lipofectamine 2000 (Invitrogen; 
Carlsbad, CA) as previously reported16,17,28,38,57.
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Figure 8. Sox2 and VRK1 levels are downregulated during NT2 cell differentiation induced by retinoic 
acid. (a) Time course of the expression of different proteins in NT2 cells induced to differentiate with retinoic 
acid (RA). At each time point cells were lysed and the extracts were loaded in 10% acrylamide gel and analyzed 
by immunoblots. The quantification of the proteins in the immunoblots is shown in Supplementary Fig. S9.  
(b) The expression of Sox2 and VRK1 proteins in NT2 cells was detected by immunofluorescence before and 
after induction of differentiation with retinoic acid (RA). Sox2 was detected using a mouse mAb anti-Sox2  
(E-4, 1:100). VRK1 was detected using a rabbit polyclonal anti-VRK1 (1:200) antibody. (c) Effect of RA-induced 
differentiation of NT2 cells on the gene expression levels Sox2, Oct4, VRK1 and macro H2A2. Total RNA was 
extracted at the indicated times and the RT-PCR was performed using specific primers indicated in the methods 
section.
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Figure 9. Effect of the three macro-histones H2A on transcription of the VRK1 and CCND1 gene 
promoters. (a) Effect of the three macro histones on the proximal promoter of VRK1 (− 1028 + 52) detected 
in luciferase assays. (b) Dose dependent effect of macro-histones H2A on the VRK1 (− 1028 + 52) detected 
in luciferase assays. (c) Effect of macro-histones H2A on the activation of the VRK1 (− 1028 + 52) promoter 
induced by Sox2 and detected in luciferase assays. (d) Effect of the three macro histones on the proximal 
promoter of CCND1 (− 1720 + 134) detected in luciferase assays. All experiments were performed three times 
and in each experiment determinations were made in triplicate. The mean and standard deviation are shown.
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Antibodies. The antibodies used were: policlonal VRK1 (VC) and monoclonal VRK1 (1B5 or 1F6)64. VRK1 
(HPA000660, Sigma). Sox2 (D6D9, Cell Signaling; Berverly, MA,; E4, Santa Cruz; Santa Cruz, CA; Y-17, Santa 
Cruz,). Oct4 (2840, Cell Signaling), Nanog (D73G4, Cell Signaling), N-Cadherin (H-63, Santa Cruz), Vimentin 
(RV202, Abcam; Cambridge, UK). Flag epitope (Sigma-Aldrich, monoclonal M5; Sigma-Aldrich, polyclonal 
F7425). HA epitope (Santa Cruz, F-7; Sigma-Aldrich, H6908), myc epitope (06–549, Millipore; Billerica, MA; 
05–724, Millipore), GST (B-14, Santa Cruz). Cyclin D1 (M-20, Santa Cruz). Cyclin A (C-19, Santa Cruz). Rb 
(C-15, Santa Cruz). Phospho-Rb (Ser807/811)(9308, Cell Signaling). PCNA (PC10, Santa Cruz). PAX6 (PRB-
278P, Covance; Princeton, NJ), p27 (610241, BD-Transduction Laboratories; Franklin Lakes, NJ). CREB (9104, 
Cell Signaling). Phospho-CREB (Ser133) (9191, Cell Signaling). C-myc (N-262, Santa Cruz). β -actin (AC-
15, Sigma-Aldrich). Secondary antibodies goat α -Mouse IgG, DyLightTM 680 and/or goat α -Rabbit Ig-G, 
DyLightTM 800 (Thermo Fischer Scientific) were used for detection in a Li-Cor Odyssey system (Thermo Fisher 
Scientific; Waltham, MA).
Immunofluorescence and confocal microscopy. Cells were plated on 35 mm dishes with several cov-
erslips, one for each antibody to be used to avoid well variation, and transfected 24 hours later with expression 
plasmids or siRNA. Two or three days after, respectively, the slides were collected and the cells were fixed with 3% 
paraformaldehyde for 30 min at room temperature. Then the cells were treated with a solution of glycine 200 mM 
for 15 min, and then permeabilized with PBS 0,2% Triton X100 for 30 min. The cells were blocked with 1% BSA 
in PBS for 1 hour. Proteins of interest were detected by immunostaining with specific antibodies that were incu-
bated overnight or for 1 hour depending on commercial instructions. The secondary antibodies were incubated 
together (goat anti-mouse Cy3 or Cy2 and goat anti-rabbit Cy3 or Cy2 from Jackson ImmunoResearch) for 1 hour 
at room temperature. Finally cells were stained with DAPI (4′ ,6′ -diamidino-2-phenylindole) (Sigma) 1:1000 in 
PBS for 10 min at room temperature, the cells were washed with PBS and slides were mounted with Mowiol 
(Calbiochem-Merck, Darmstadt Germany), and analysed with a LEICA SP5 DMI-6000B confocal microscope. 
The lasers used were: Argon (488 nm), DPSS (561 nm) and UV Diode (405 nm). Images were captured with a 
63.0x lens zoomed in 1.5–3× with a 1024 × 1024 frame and 600 Hz scanning speed. Microscope scanner settings 
were maintained constant for image capture for all samples. Images were analysed with ImageJ (NIH, http://rsb.
info.nih.gov/ij) and the intensity of cellular immunofluorescence was quantified with the LAS Lite program (Leica 
Microsystems, Wetzlar, Germany).
Immunoprecipitation assays. Cells were lysed as previously reported19,38,65. Immunoprecipitations were 
performed with Gammabind G-Plus Sepharose beads (Amersham Biosciences) as described22,27,64. Briefly for 
immunoprecipitation experiments, cells were grown in 100-mm dishes and were transfected with different plas-
mids tagged with myc-Flag or HA epitopes. The amount and type of the specific plasmid is indicated in each indi-
vidual experiment. Whole cells extracts prepared 36 hours after transfection were lysed in lysis buffer containing 
50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% Nonidet, 1 mM EDTA, 1 mM sodium orthovanadate, 1 mM NaF 
and protease inhibitors as follows: 10 μ g/mL leupeptin, 10 μ g/mL aprotinin, 1 mM PMSF. Extracts were incubated 
on ice for 20 min and precleared by centrifugation at 14,000 rpm for 20 min at 4 °C. Then, extracts were immu-
noprecipitated with the specific antibody for each experiment. Immune complexes were recovered with γ -Bind 
G Sepharose (GE Healthcare Pharmacia). Beads were washed five times with lysis buffer and subjected to elec-
trophoresis followed by immunoblot analysis with the corresponding antibodies indicated in each experiment.
Immunohistochemistry. Biopsies from normal human amygdala were obtained with informed con-
sent, fixed in formalin and embedded in paraffin. Immunodetection was performed with the DAKO EnVision 
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Figure 10. Diagram of the Sox2 and VRK1 roles in the regulation of cell proliferation and differentiation. 
As cells enter proliferate there is an increase in Sox2 levels that activate VRK1 and CCND1 gene expression. In 
this activation also participates VRK1. As cells enter the differentiation progress there is an accumulation of cell 
cycle inhibitors, a reduction of Sox2 and VRK1 as well as an increase in terminally differentiation markers, such 
as NCAM, nestin and Pax6. In differentiated cells there is also a change in the pattern of macro histones and an 
accumulation of macro H2A1.1 and macro H2A2. The triangles represent the increase or decrease of different 
markers; for Sox2, VRK1 and CCND1 in blue, and for NCAM, Nestin and Pax6 in orange. Red lines indicate 
inhibition, and green lines indicate activation.
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Visualization Method (DAKO) with diaminobenzidine chromogen. Sections were counterstained with haema-
toxylin. VRK1 was detected with the VC polyclonal antibody (1:30) and Sox2 with monoclonal antibody Sox2 
(E-4, 1:30). For immunofluorescence, the tissue sections, after antigen retrieval, and incubated with both the 
primary antibodies together (1:30 each one). The sections were incubated with the secondary antibodies α -mouse 
Cy3 (1:100) (Jackson ImmunoResearch) and α -rabbit Alexa Fluor 488 (1:100) (Molecular Probes; Eugene, OR). 
Cells were mounted with Vectashield (Vector Laboratories, Burlingame, CA) and analyzed with a LEICA SP5 
DMI-6000B (Leica Microsystems) as reported28,38.
Kinase assay. An in vitro kinase assay using GST-VRK1 or kinase-dead GST-VRK1(K179E) purified from 
bacteria was used in the assay with immunoprecipitated myc-Sox2 as substrate. The conditions for the in vitro 
kinase assay as reported66. Briefly VRK kinase activity was determined by assaying protein phosphorylation 
in a final volume of 30 μ L containing kinase buffer (20 mM Tris-HCl pH 7.5, 5 mM MgCl2, 0.5 mM DTT and 
150 mM KCl), 5 μ M ATP and 5 μ Ci of [γ 32P]ATP with 2 μ g of GST-VRK1 and the immunoprecipitated Sox2 pro-
tein. The proteins in the assay were analysed by electrophoresis in 12.5% SDS-polyacrilamide gels. The gels were 
stained with Coomassie Blue or proteins were transferred to PVDF membrane and the incorporated activity was 
measured66.
Immunoblots. Protein extracts were quantified using the Protein assay kit (Bio-Rad; Hercules, CA). Protein 
were fractionated in a SDS polyacrylamide gel and transferred to a PVDF Immobilon-P or Immobilon-FL mem-
branes (Millipore) as reported24,38,58. PDVF membranes were blocked for 1 hour, or overnight, at room tempera-
ture with 5% defatted milk in TBS-T buffer (25 mM Tris-HCl pH 8, 50 mM NaCl, 2,5 mM KCl, 0,1% Tween-20). 
Membranes were incubated with the primary antibody for 1 hour at room temperature or overnight at 4 °C fol-
lowed by extensive washing in TBS-T buffer. Next, membranes were incubated with the corresponding secondary 
antibody for 30 minutes at room temperature followed by washing. Membrane signals were detected and quanti-
fied using in a Li-Cor Odyssey system (Thermo-Fisher)28. Alternatively, some western blotss were also analysed 
with the ECL Western Blotting Detection Reagents” (GE Healthcare) and luminescence detected using X-ray film.
qRT-PCR. RNA (100 ng) was used in a one-step qRT-PCR using the t iScriptTM One-Step RT-PCR Kit 
With SYBR® Green (Bio-Rad). The primers used were: Sox2 (forward: 5′-CCCGGATCCGCCATGTACAAC 
ATGATGGAGACGGAGCTG-3′; reverse: 5′-CCCGAATTCGCCTCACATGTGTGAGAGGGGCAGTGTG 
CC-3); VRK1 (forward: 5′-CCAACGAGCTGCAAAACC-3′; reverse: 5′-TGTCATGTAGACCAGACCCCC-3′); 
Oct4 (forward: 5′-AAGCGATCAAGCAGCGACTAT-3′; reverse: 5′- GGAAAGGGACCGAGGAGTACA-3′); 
GAPDH (forward: 5′-GGTCTTACTCCTTGGAGGCCATGT-3′; reverse: 5′-ACCTAACTACATGGTTT 
ACATGTT-3′); macroH2A2 Primers: macroH2A2 (forward: 5′-TGCTGGCAGTTGCCAATGACGA-3′; reverse: 
5′-CGTTTCCGACTTGCCTTTGGTC-3′; macroH2A1.2 Primers (forward: 5′- CTGAACCTTATTCACAGTG 
AAATCAGT-3′; reverse: 5′- GTGTTTCCTAGGTCATCTTTAAGGT - 3′).
Luciferase assay. MDA-MB-231 and HEK293T cells were transfected with different amounts of Sox2, 
tagged with myc-Flag (pCMV6-myc-Flag-Sox2) and pGL2-B-VRK1 (− 1028 + 52) or 0.5 μ g of pGL2-B-VRK1 
(− 264 + 52) vectors. Cyclin D1 promoter: pA3- Cyclin D1(− 1745 + 134)-Luc59. pGL2-basic was used as negative 
control. Luciferase activity was determined with a Dual luciferase reporter system from Promega (Madison, WI) 
following the manufacturer instructions as previously reported29,67.
Retinoic acid differentiation. For all-trans retinoic acid (RA) (Sigma-Aldrich) differentiation of NT2, 
1.6 × 105 cells were seeded in 100 mm culture dishes and treated during 14 days with 10 μ M RA as previous 
described61.
Database of protein interactions. The protein interactions from this publication have been submitted to 
the IMEx (http://www.imexconsortium.org) consortium through IntAct database68 and assigned the identifier 
IM-24906.
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Supplementary Figure S1. a. Nuclear colocalization of Sox 2 and VRK1 in nuclei of MCF7 and MDA-MB-
231 cells was detected by confocal immunofluorescence microscopy. Sox2 (murine monoclonal antibody) and
VRK1 (rabbit polyclonal VC1). b. Level of nuclear Sox2 protein in four cell lines cell lines. Nuclear
fluorescence was quantified with the image J program. In the graph to the right is shown the relative level in
each cell line. The mean and standard deviations are shown.
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Supplementary Figure S2. A. Sox2 interacts with VRK1. a. The transfected VRK1 and SOX2 interact one with
each other, being the interaction dependent of Sox2 levels. The 293T cells were transfected, with Sox2 (pCMV6-
Flag-myc-Sox2), with wild-type VRK1 (pCEFL HA-VRK1). 48 later the cells were lysed and the extracts
immunoprecipitated with a rabbit polyclonal anti-Flag (F7425) antibody or with rabbit polyclonal anti-HA
(H6908) antibody. The immunoprecipitates were loaded in a 10% acrylamide gel. HA-VRK1 was detected with
anti-HA mAb (16B12). Endogenous VRK1 was detected using a anti-VRK1 (1B5) antibody. Flag-tagged Sox2
was detected with anti-Flag murine mAb (F4042) antibody (1:1000). Human β-Actin was detected using a mouse
monoclonal anti-β-Actin antibody. b. Dose dependent interaction between Sox2 and VRK1. The 293T cells were
transfected, with Sox2 (pCMV6-Flag-myc-Sox2), with increasing amounts of wild-type VRK1 (pCEFL HA-
VRK1). Sox2 was immunoprecipitated and the presence of VRK1 determined as in part a. c. The 293T cells were
transfected with Sox2 (pCMV6-Flag-myc-Sox2), and different constructions of VRK1 protein: GST-tagged
VRK1 (pGEX-GST-VRK1), carboxy terminal GST-VRK1(267-369) and truncated VRK1 (pGEX-GST-VRK1
(R358X). 48 hours later the cells were lysed and the extracts were immunoprecipitated with a polyclonal anti-flag
(F7425) antibody. The immunoprecipitates were loaded in a 10% acrylamide gel. Wild type GST-VRK1, GST-
VRK1 carboxy-terminal and GST-VRK1(R358X) were detected using a mouse monoclonal anti-GST (B-14).
Human SOX2 was detected using a mouse monoclonal anti-flag (F4042 β-Actin was detected using a mouse
monoclonal anti-β-Actin antibody. d. The 293T cells were transfected with myc-tagged, wild-type VRK1
(pcDNA3.1-VRK1) and amino terminal VRK1 (pcDNA3.1-VRK1(1-332)). 48 hours later the cells were lysed
and the extracts were incubated with a mouse monoclonal anti-Sox2 (E-4) antibody overnight. After the
immunoprecipitation, the extracts were loaded in a 10% acrylamide gel. Wild-type VRK1 and VRK1 amino
terminal were detected using a rabbit polyclonal anti-myc, endogenous Sox2 was detected using a goat polyclonal
(Y-17) antibody and human β-Actin was detected using a mouse monoclonal anti-β-actin antibody.
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Supplementary Figure S3. Sox2 activates endogenous VRK1 gene expression in
MCF7 cells. a. Effect of overexpression of Sox2 expressed in breast cancer MCF7 cells
that were infected with the retroviral plasmid pBabe-Sox2. Cells were studied by
confocal immunofluorescence. The quantification of the fluorescence is shown in the
graph to the right. b. Fluorescence of nuclear VRK1 protein after infection with empty
vector (pBabe) or with pBabe-Sox2. c. Effect of Sox2 overexpression in MCF7 cells on
endogenous VRK1 protein determined in cell lysates by immunoblot.
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Supplementary Figure S4. Sox2 activates the human VRK1 gene promoter. a. Dose-dependent
activation of the VRK1 gene promoter by expression of Sox2. Two plasmids expressing regions from the
long proximal VRK1 promoter (-1028 to + 52) cloned in pGL2-b-luciferase vector and Renilla-luciferase as
internal control were transfected in HEK293T cells with different amounts of plasmid Flag-2-Sox2. b. Lack
of Dose-dependent activation of the VRK1 gene short promoter (-264 to + 52), cloned in pGL2-b-luciferase
vector, by expression of increasing amounts of Sox2. Renilla-luciferase was used as internal control. The
PGL2-Control is a plasmid expressing luciferase under the SV40 promoter used as positive control. pGL2-
basic,, a promoterless plasmid, was used as negative and background control. Plasmid expression was also
confirmed by immunoblot. Human β-actin was detected using a mouse monoclonal anti-β-actin antibody
(Sigma-Aldrich; St. Louis, MO, USA) (1:5000). (Student’s Test:*<0,05; **<0,005; ***<0,0005).
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Supplementary Figure S5. Effect of VRK1 knockdown on Sox2 in MCF-7 cells. a. Sox2 protein and
fluorescence levels increase when VRK1 levels decrease in MCF7 cells. In immunofluorescence, human
endogenous Sox2 was detected with a mouse monoclonal anti-Sox2 (E-4). Human endogenous VRK1 was
detected using a rabbit polyclonal anti-VRK1 antibody. Human endogenous VRK1 was detected, by Western
Blot, using a murine mAb anti-VRK1 (1B5). Human endogenous Sox2 was detected using a goat polyclonal
anti-Sox2 (Y-17). and human β-actin was detected using a mouse monoclonal anti-β-Actin antibody. b.
Depletion of VRK1 results in an increase of Sox2 mRNA. 72 hours after siControl, si-VRK1-02 and si-
VRK1-09 treatment, was performed the fixation and permeabilization of MCF-7 cells. For expression
analysis, MCF-7 cells were transfected with siControl (siCt), siVRK1-02 (siV-02) or siVRK1-03 (siV-03) and
72hours later the mRNA was extracted. The qRT-PCR was performed using primers for VRK1, Sox2 and
GAPDH.
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Supplementary Figure S6 – Effect of VRK1 knockdown on the Sox2 levels in NT2 cells. 72 hours
after siControl (siCt), si-VRK1-02 (siV-02) and si-VRK1-03 (siV-03) treatment, was performed the
fixation and permeabilization of Ntera-2 cells. By immunofluorescence, human endogenous Sox2 was
detected with a rabbit polyclonal anti-Sox2 antibody. Human endogenous VRK1 was detected using a
rabbit polyclonal anti-VRK1 antibody. DAPI (1:1000). For immunoblot analysis, cells were harvested,
lysed and loaded in a 10% acrylamide gel. Human endogenous VRK1 was detected using an anti-
VRK1murine mAb (1B5) antibody. Human endogenous Sox2 was detected using a rabbit polyclonal
anti-Sox2 antibody, and human β-actin was detected using a murine mAb anti-β-actin antibody.
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Supplementary Figure S7. Effect of VRK1 overexpression on Sox2 gene expression in HeLa cells.
HeLa cells were infected with a retroviral plasmid (pQCXIP) or a construct expressing VRK1 (pQCXIP-
VRK1). Cells were grown in the presence of puromycin and used as a pool.. a. Detection of the nuclear
levels of VRK1 and Sox2 detected by confocal immunofluorescence. To the right is shown the
quantification of individual cells. b. Effect of VRK1overexpression on Sox2 mRNA in a stable HeLa cells
used as a pool. Total RNA was extracted from stable cell lines infected with either pQCXIP (control
vector) or pQCXIP-VRK1. This RNA was used for quantification by qRT-PCR with VRK1 and Sox2
specific primers. Result is the mean of two experiments.
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Supplementary Figure S8. Diferentiation of NT2 cells induced by retinoic acid. a.Loss of expression
of Sox2, Oct4 and nanog in RA differentiated NT2 cells by confocal microscopy (left column).
Reorganization of α-tubulin induced by retinoic acic (second column). b. Detection of several markers in
non-treated and treated(differentiated cells).
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Supplementary Figure S9. Quantification of the immunoblots in Figure 7 showing the differentiation of
NT-2 cells induced by RA.
